Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. (-)-8-(4-(2-butoxyethoxy)phenyl)-1-isobutyl-n-(4-(((1-propyl-1h-imidazol-5-yl)methyl)sulfinyl)phenyl)-1,2,3,4-tetrahydro-1-benzazocine-5-carboxamide
2. 8-(4-(2-butoxyethoxy)phenyl)-1,2,3,4-tetrahydro-1-(2-methylpropyl)-n-(4-((s)-((1-propyl-1h-imidazol-5-yl)methyl)sulfinyl)phenyl)-1-benzazocine-5-carboxamide
3. Tak 652
4. Tak-652
5. Tbr 652
6. Tbr-652
7. Tbr652
1. Tbr-652
2. 497223-25-3
3. Tak-652
4. Tbr652
5. Tbr 652
6. 15c116ua4y
7. 497223-25-3 (free Base)
8. (-)-8-(4-(2-butoxyethoxy)phenyl)-1-isobutyl-n-(4-(((1-propyl-1h-imidazol-5-yl)methyl)sulfinyl)phenyl)-1,2,3,4-tetrahydro-1-benzazocine-5-carboxamide
9. (s,e)-8-(4-(2-butoxyethoxy)phenyl)-1-isobutyl-n-(4-(((1-propyl-1h-imidazol-5-yl)methyl)sulfinyl)phenyl)-1,2,3,4-tetrahydrobenzo[b]azocine-5-carboxamide
10. Cvc
11. Tak 652
12. Tak652
13. Cenicrivirocum
14. Cenicriviroc [inn]
15. Cenicriviroc (usan/inn)
16. Cenicriviroc [usan:inn]
17. Cenicriviroc [usan]
18. Cenicriviroc [who-dd]
19. Unii-15c116ua4y
20. Schembl3157748
21. Schembl3157768
22. Chembl2110727
23. Tbr-652tak-652
24. Chebi:149636
25. (5e)-8-[4-(2-butoxyethoxy)phenyl]-1-(2-methylpropyl)-n-[4-[(s)-(3-propylimidazol-4-yl)methylsulfinyl]phenyl]-3,4-dihydro-2h-1-benzazocine-5-carboxamide
26. Amy12051
27. Ex-a1608
28. Tak-652; Tbr-652
29. Bdbm50306033
30. Bdbm50422828
31. Mfcd28502076
32. S8512
33. Cs-6148
34. Db11758
35. 8-(4-(2-butoxyethoxy)phenyl)-1,2,3,4-tetrahydro-1-(2-methylpropyl)-n-(4-((s)-((1-propyl-1h-imidazol-5-yl)methyl)sulfinyl)phenyl)-1-benzazocine-5-carboxamide
36. Ac-31368
37. As-35184
38. Bc179068
39. Hy-14882
40. D09878
41. Q5058846
42. (5e)-8-[4-(2-butoxyethoxy)phenyl]-1-(2-methylpropyl)-n-(4-{(s)-[(1-propyl-1h-imidazol-5-yl)methyl]sulfinyl}phenyl)-1,2,3,4-tetrahydro-1-benzazocine-5-carboxamide
43. (5e)-8-[4-(2-butoxyethoxy)phenyl]-1-isobutyl-n-[4-[(s)-(3-propylimidazol-4-yl)methylsulfinyl]phenyl]-3,4-dihydro-2h-1-benzazocine-5-carboxamide
44. (s)-8-(4-(2-butoxyethoxy)phenyl)-1-(2-methylpropyl)-n-(4-(((1-propyl-1h-imidazol-5- Yl)methyl)sulfinyl)phenyl)-1,2,3,4-tetrahydro-1-benzazocine-5-carboxamide
45. 1-benzazocine-5-carboxamide, 8-(4-(2-butoxyethoxy)phenyl)-1,2,3,4-tetrahydro-1-(2- Methylpropyl)-n-(4-((s)-((1-propyl-1h-imidazol-5-yl)methyl)sulfinyl)phenyl)-
46. 1-benzazocine-5-carboxamide, 8-(4-(2-butoxyethoxy)phenyl)-1,2,3,4-tetrahydro-1-(2-methylpropyl)-n-(4-((s)-((1-propyl-1h-imidazol-5-yl)methyl)sulfinyl)phenyl)-
47. 1-benzazocine-5-carboxamide, 8-[4-(2-butoxyethoxy)phenyl]-1,2,3,4-tetrahydro-1-(2-methylpropyl)-n-[4-[[(1-propyl-1h-imidazol-5-yl)methyl]sulfinyl]phenyl]-, (5e)-
48. 8-(4-(2-(butoxy)ethoxy)phenyl)-1-(2-methylpropyl)-n-(4-((s)-((1-propyl-1h-imidazol-5-yl)methyl)sulfinyl)phenyl)-1,2,3,4-tetrahydro-1-benzazocine-5-carboxamide
| Molecular Weight | 696.9 g/mol |
|---|---|
| Molecular Formula | C41H52N4O4S |
| XLogP3 | 7.5 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 7 |
| Rotatable Bond Count | 17 |
| Exact Mass | 696.37092733 g/mol |
| Monoisotopic Mass | 696.37092733 g/mol |
| Topological Polar Surface Area | 105 Ų |
| Heavy Atom Count | 50 |
| Formal Charge | 0 |
| Complexity | 1060 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Treatment of non-alcoholic steatohepatitis (NASH)
CCR5 Receptor Antagonists
Compounds and drugs that inhibit or block the activity of CCR5 RECEPTORS. (See all compounds classified as CCR5 Receptor Antagonists.)
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Cenicriviroc manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Cenicriviroc, including repackagers and relabelers. The FDA regulates Cenicriviroc manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Cenicriviroc API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Cenicriviroc supplier is an individual or a company that provides Cenicriviroc active pharmaceutical ingredient (API) or Cenicriviroc finished formulations upon request. The Cenicriviroc suppliers may include Cenicriviroc API manufacturers, exporters, distributors and traders.
Cenicriviroc Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Cenicriviroc GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Cenicriviroc GMP manufacturer or Cenicriviroc GMP API supplier for your needs.
A Cenicriviroc CoA (Certificate of Analysis) is a formal document that attests to Cenicriviroc's compliance with Cenicriviroc specifications and serves as a tool for batch-level quality control.
Cenicriviroc CoA mostly includes findings from lab analyses of a specific batch. For each Cenicriviroc CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Cenicriviroc may be tested according to a variety of international standards, such as European Pharmacopoeia (Cenicriviroc EP), Cenicriviroc JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Cenicriviroc USP).
LOOKING FOR A SUPPLIER?
